Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia

Status Recruiting

Clinical Trial Summary

This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 target CAR iPSC NK cells in patients with relapsed/refractory AML

Clinical Trial Description

Acute myelogenous leukemia (AML) is a potentially cur-able disease; 70% of newly diagnosed patients achievecomplete remission with first-line therapy, but prognosisworsens for relapsed disease in both pediatric and adultpatients. CLL-1 has attracted the researchers' attention due to its high expression in AML while being absent in normal hematopoietic stem cell. Accumulating evidence have demonstrated CLL-1 is an ideal target for AML. ;

Study Design

Related Conditions & MeSH terms

AML, Adult

Clinical Trial Details

NCT number	NCT06027853
Study type	Interventional
Source	Zhejiang University
Contact	He Huang, MD
Phone	+8613605714822
Email	hehuangyu@126.com
Status	Recruiting
Phase	Phase 1
Start date	September 10, 2023
Completion date	August 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04623944` - NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS	Phase 1
Not yet recruiting	`NCT06313437` - Revumenib in Combination With 7+3 + Midostaurin in AML	Phase 1
Terminated	`NCT04079738` - Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib	Phase 1/Phase 2
Recruiting	`NCT06052813` - A Study of BN104 in the Treatment of Acute Leukemia	Phase 1/Phase 2
Completed	`NCT02986620` - Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia
Recruiting	`NCT05601466` - Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT06066905` - A Study of Chidamide With AZA in MRD Positive AML After Transplant	N/A
Recruiting	`NCT05909501` - Assessment of Geriatric Evaluations Impact on New AML Guidance
Terminated	`NCT04614636` - FT538 in Subjects With Advanced Hematologic Malignancies	Phase 1
Not yet recruiting	`NCT06420063` - Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML	Phase 1/Phase 2
Withdrawn	`NCT04128020` - Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia	Phase 1
Active, not recruiting	`NCT04749355` - Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS	Phase 2
Active, not recruiting	`NCT04755244` - A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)	Phase 1/Phase 2
Completed	`NCT03194685` - Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Recruiting	`NCT03884829` - A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS	Phase 1
Active, not recruiting	`NCT05177731` - Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML	Phase 3
Not yet recruiting	`NCT06377579` - OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
Recruiting	`NCT05025098` - Precision Therapy Versus Standard Therapy in AML and MDS in Elderly	Phase 2
Not yet recruiting	`NCT06263387` - Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
Not yet recruiting	`NCT06188182` - D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia